✦ LIBER ✦

Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: Implications for the treatment of patients with metastatic melanoma

✍ Scribed by Omar Eton; Moshe Talpaz; Kyoo H. Lee; Jeanne M. Rothberg; Joanna M. Brell; Robert S. Benjamin

Publisher: John Wiley and Sons
Year: 1996
Tongue: English
Weight: 664 KB
Volume: 77
Category: Article
ISSN: 0008-543X
DOI: 10.1002/(sici)1097-0142(19960301)77:5<893::aid-cncr13>3.0.co;2-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I trial of subcutaneous recombinan

Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma

✍ Omar Eton; Michael G. Rosenblum; Sewa S. Legha; Wehei Zhang; Mary Jo East; Agop 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 3 views

## Abstract ## BACKGROUND Interleukin‐2 (IL‐2) has activity in metastatic melanoma when given in high doses by the intravenous (IV) route, but its side effects and effectiveness when given in intermediate to high doses by the subcutaneous (SC) route have not been studied adequately. This study sou

Clinical phase II trial of recombinant d

Clinical phase II trial of recombinant dna interferon (interferon alfa 2b) in patients with metastatic malignant melanoma

✍ Thierry Dorval; Thao Palangie; Michel Jouve; Emilio Garcia-Giralt; Lucien Israel 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 381 KB 👁 3 views

A phase I-II trial of the combination of

A phase I-II trial of the combination of recombinant leukocyte a interferon and recombinant human interferon-γ in patients with metastatic malignant melanoma

✍ Edward T. Creagan; Charles L. Loprinzi; David L. Ahmann; Daniel J. Schaid 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 325 KB 👁 2 views

A phase I study of recombinant human int

A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma

✍ A. Mittelman; M. Huberman; C. Puccio; B. Fallon; J. Tessitore; S. Savona; R. Eyr 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 662 KB

Preclinical data suggest synergy of interleukin-2 (IL-2) combined with alphainterferon (IFN). In addition, toxicities of IL-2 may be decreased by intermittent continuous infusion. The purpose of this trial was to determine the maximum tolerated dose (MTD) of recombinant IL-2 combined with alpha-IFN

A Phase II trial of 5-fluorouracil and r

A Phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma

✍ Richard Pazdur; Jaffer A. Ajani; Rodger Winn; James Bearden; Robert J. Belt; Sus 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 468 KB 👁 3 views

A Phase I1 clinical trial of the combination of 5-fluorouracil (5-FU) and recombinant alpha-2a-interferon (a-2a-IFN) was conducted in 44 patients. Patients had not received chemotherapy previously and had measurable metastatic gastric carcinoma. 5-FU was administered as a continuous infusion at a do

A Phase II study of “decrescendo” interl

A Phase II study of “decrescendo” interleukin-2 plus interferon-α-2a in patients with progressive metastatic melanoma after chemotherapy

✍ Omar Eton; Antonio C. Buzaid; Agop Y. Bedikian; Teresa M. Smith; Nicholas E. Pap 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

The authors tested a biotherapy regimen involving recombinant interferon-␣-2a (rIFN-␣-2a) and recombinant human interleukin-2 (rhIL-2), given in a "decrescendo" schedule over 5 days, for its activity and toxicity in 21 patients who previously had received chemotherapy for advanced melanoma. ## METH